Holen Sie sich die Stockscreener-App
5.86
0.86%
0.05
Handel nachbörslich:
5.86
Kura Oncology Inc Aktie (KURA) Neueste Nachrichten
Transcript : Kura Oncology, Inc.Special Call - MarketScreener
Kura Oncology Announces Positive Phase 1a/1b Trial Results - TipRanks
Long Term Trading Analysis for (KURA) - news.stocktradersdaily.com
Kura Oncology rises after new early-stage trial data for leukemia therapy - MSN
Pallas Capital Advisors LLC Invests $66,000 in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology, Inc. (NASDAQ:KURA) Shares Sold by Harbor Capital Advisors Inc. - Defense World
Kura Oncology’s SWOT analysis: ziftomenib’s potential reshapes AML treatment stock outlook By Investing.com - Investing.com South Africa
Kura Oncology’s SWOT analysis: ziftomenib’s potential reshapes AML treatment stock outlook - Investing.com Canada
KURA's Ziftomenib Shows Promising Results in AML Clinical Trial - GuruFocus
Kura Oncology reports positive data for AML treatment ziftomenib By Investing.com - Investing.com South Africa
Is the Options Market Predicting a Spike in Kura Oncology Stock? - The Globe and Mail
Kura Oncology (KURA) Shows Promising Results for AML Therapy - GuruFocus
Kura Oncology Says Ziftomenib Study Achieves Complete Remission in Acute Myeloid Leukemia - MarketScreener
Kura Oncology stock rises on leukemia drug data (KURA:NASDAQ) - Seeking Alpha
Is The Options Market Predicting A Spike In Kura Oncology Stock? - Barchart.com
Kura Oncology and Kyowa Kirin Report Positive Updated Combinatio - GuruFocus
Kura Oncology’s SWOT analysis: ziftomenib stock potential in AML treatment By Investing.com - Investing.com Canada
Kura Oncology and Kyowa Kirin Report Strong Results from KOMET-007 Trial of Ziftomenib in Newly Diagnosed AML Patients - Nasdaq
Kura Oncology reports positive data for AML treatment ziftomenib - Investing.com
Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly ... - Enidnews.com
Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress - Yahoo Finance
Kura Oncology’s SWOT analysis: ziftomenib stock potential in AML treatment - Investing.com
Cantor Fitzgerald Forecasts Kura Oncology FY2026 Earnings - Defense World
KURA Stock Rises More Than 15% This Past Week: Here's Why - MSN
Kura Oncology at Goldman Sachs Conference: Strategic Insights on ZIFTOMENIB - Investing.com Canada
Transcript : Kura Oncology, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 11 - marketscreener.com
Kura Oncology, Inc. (NASDAQ:KURA) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Ameriprise Financial Inc. Acquires New Position in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology Stockholders Approve Equity Plan Amendment - TipRanks
Kura Oncology Grants Stock Options To New Hires Under Inducement Plan - Nasdaq
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rul - GuruFocus
Kura Oncology (KURA) Grants Stock Options to New Employees | KUR - GuruFocus
Kura Oncology (KURA) Grants Stock Options to New Employees | KURA Stock News - GuruFocus
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | KURA Stock News - GuruFocus
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Kura Oncology Expands Cancer Research Team with Strategic Stock Options for 5 Key New Hires - Stock Titan
Kura Oncology’s (KURA) “Market Outperform” Rating Reaffirmed at JMP Securities - Defense World
Kura Oncology at Jefferies Conference: Strategic Advancements in AML By Investing.com - Investing.com Canada
**citizens jmp reiterates market outperform rating on kura oncology stock** - Investing.com UK
Two Sigma Investments LP Sells 42,120 Shares of Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Rising Leaders 2025: Kura Oncology’s Mollie Leoni On Setting Precedent, Not Following It - insights.citeline.com
Nuveen Asset Management LLC Lowers Stock Position in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Transcript : Kura Oncology, Inc. Presents at American Society of Clinical Oncology Annual Meeting 2025, Jun-02-2025 06 - marketscreener.com
Kura Oncology Drug’s Data at ASCO Support FDA Filing Now Under Priority Review for Leukemia - MedCity News
KURA: Optimism for Kura Oncology's Menin Inhibitor Grows with FDA Priority Review | KURA Stock News - GuruFocus
Cantor Fitzgerald reiterates overweight rating for Kura Oncology stock By Investing.com - Investing.com Nigeria
Kura Oncology reports positive trial results for AML treatment By Investing.com - Investing.com South Africa
Kura Oncology at ASCO: Strategic Moves in AML Treatment By Investing.com - Investing.com Canada
Kura Oncology reports positive trial results for AML treatment - Investing.com Australia
KURA: Promising Results for Kura Oncology's AML Therapy at ASCO Meeting | KURA Stock News - GuruFocus
0.68%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):